<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04822363</url>
  </required_header>
  <id_info>
    <org_study_id>2021-P-000134</org_study_id>
    <nct_id>NCT04822363</nct_id>
  </id_info>
  <brief_title>The Accuracy Of A Novel Platelet Activity Assay In Humans On Antiplatelet Agents: Pharmacodynamics And Comparison With Light Transmission Aggregometry</brief_title>
  <official_title>The Accuracy Of A Novel Platelet Activity Assay In Humans On Antiplatelet Agents: Pharmacodynamics And Comparison With Light Transmission Aggregometry</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beth Israel Deaconess Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institutes of Health (NIH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Beth Israel Deaconess Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to test a novel diagnostic immunoassay of platelet function and&#xD;
      compare it to the current gold standard platelet function assay by testing the response to&#xD;
      aspirin and clopidogrel in a group of healthy volunteers and severely obese individuals and&#xD;
      comparing the accuracy of the two tests. The secondary goals will be to evaluate the&#xD;
      pharmacodynamic parameters of the antiplatelet agents across the two testing modalities and&#xD;
      refine the cutoffs used for the novel assay.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">August 15, 2021</start_date>
  <completion_date type="Anticipated">April 2025</completion_date>
  <primary_completion_date type="Anticipated">April 2023</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Comparison at day 5 of pDrp1 Assay relative to Light Transmission Aggregometry</measure>
    <time_frame>5 days</time_frame>
    <description>Sensitivity of pDrp1 assay for platelet inhibition at day 5</description>
  </primary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">125</enrollment>
  <condition>Platelet Activation Testing Before/After Anti-platelet Therapy</condition>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Group A: Healthy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Low Dose Aspirin - 81mg daily for 7 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B: Healthy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>High Dose Aspirin - 325mg daily for 7 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group C: Healthy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Clopidogrel 300mg on Day 1 and 75mg daily for 6 subsequent days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group D: Obese</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Low Dose Aspirin - 81mg daily for 7 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group E: Obese</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Clopidogrel 300mg on Day 1 and 75mg daily for 6 subsequent days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aspirin</intervention_name>
    <description>Low dose aspirin in Arms A and D and High Dose Aspirin in Arm B</description>
    <arm_group_label>Group A: Healthy</arm_group_label>
    <arm_group_label>Group B: Healthy</arm_group_label>
    <arm_group_label>Group D: Obese</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clopidogrel</intervention_name>
    <description>Arms C and E</description>
    <arm_group_label>Group C: Healthy</arm_group_label>
    <arm_group_label>Group E: Obese</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Subject is ≥18 years of age&#xD;
&#xD;
          2. Subject is willing to participate and provide informed consent&#xD;
&#xD;
          3. Subject is considered reliable and capable of adhering to the protocol per the&#xD;
             judgment of the Investigator&#xD;
&#xD;
          4. Groups A, B and C: BMI between 18 and 30 kg/m2; Groups D and E: BMI ≥ 35 kg/m2&#xD;
&#xD;
          5. Subjects must be age ≥ 18 years old&#xD;
&#xD;
          6. Serum Creatinine &lt; 1.3 mg/dL&#xD;
&#xD;
          7. Platelet count ≥ 150 K/uL&#xD;
&#xD;
          8. Hematocrit ≥ 38%&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Pregnant. If female of child-bearing age, negative urinary pregnancy test required at&#xD;
             time of enrollment. Women of child-bearing potential must agree to use adequate&#xD;
             contraception (hormonal or barrier method of birth control; abstinence) prior to study&#xD;
             entry and for the duration of study participation. Should a woman become pregnant or&#xD;
             suspect she is pregnant she should inform her treating physician immediately.&#xD;
&#xD;
          2. Established diagnosis of cirrhosis or active cancer&#xD;
&#xD;
          3. History of allergy to aspirin or clopidogrel&#xD;
&#xD;
          4. Any history of taking aspirin, antiplatelet drugs, NSAIDS, cyclooxygenase (COX)-2&#xD;
             inhibitors, warfarin, low-molecular weight heparin, thrombolytic agents, or other&#xD;
             anticoagulants (such as direct thrombin inhibitors or factor X inhibitors) within 2&#xD;
             weeks prior to enrollment. (Refer to appendix)&#xD;
&#xD;
          5. Use of certain antibiotics, cardiovascular drugs, lipid-lowering agents,&#xD;
             antidepressants, antihistamines, non-prescription drugs, and supplements within the&#xD;
             past 2 weeks. (Refer to appendix)&#xD;
&#xD;
          6. Any major illness requiring hospitalization or surgery in the previous six months.&#xD;
&#xD;
          7. Personal history of gastrointestinal bleed in the last 24 months or diagnosis of&#xD;
             peptic ulcer disease in the last 12 months&#xD;
&#xD;
          8. Lifetime personal history of hemorrhagic stroke.&#xD;
&#xD;
          9. Personal or family history of bleeding diatheses, including hemophilias, von&#xD;
             Willebrand's disease, Bernard-Soulier syndrome, or Glanzmann thrombasthenia (unless&#xD;
             otherwise confirmed not present in study subject)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jeffrey Zwicker, MD</last_name>
    <phone>617-667-9920</phone>
    <email>jzwicker@bidmc.harvard.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Pavania Elavalakanar, MSc</last_name>
    <phone>617-667-1903</phone>
    <email>pelavala@bidmc.harvard.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Beth Israel Deaconess Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jeffrey Zwicker, MD</last_name>
      <phone>617-667-9920</phone>
      <email>jzwicker@bidmc.harvard.edu</email>
    </contact>
    <contact_backup>
      <last_name>Pavania Elavalakanar, MSc</last_name>
      <phone>617-667-1903</phone>
      <email>pelavala@bidmc.harvard.edu</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>March 26, 2021</study_first_submitted>
  <study_first_submitted_qc>March 26, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 30, 2021</study_first_posted>
  <last_update_submitted>August 3, 2021</last_update_submitted>
  <last_update_submitted_qc>August 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Beth Israel Deaconess Medical Center</investigator_affiliation>
    <investigator_full_name>Jeff Zwicker</investigator_full_name>
    <investigator_title>Attending Physician, Associate Professor</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
    <mesh_term>Clopidogrel</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

